SCHEMBL17633151

SCHEMBL17633151

COC(=O)c1ccc2c(c1)ncn2COCC[Si](C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 2/20 0.51
▸ BRD4 O60885 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ POLB P06746 3/20 0.43
▸ MAPT P10636 1/20 0.43
▸ NPC1 O15118 3/20 0.41
▸ MAPK1 P28482 3/20 0.41
▸ LMNA P02545 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ USP2 O75604 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ HPGD P15428 3/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ MKNK1 Q9BUB5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17633169 0.91 BRD4 (0.48) FGFR1BRD4KDM4EPOLBMAPT
SCHEMBL25427962 0.80 FGFR1 (0.40) FGFR1BRD4KDM4EMAPTNPC1
SCHEMBL31150496 0.80 FGFR1 (0.40) FGFR1BRD4KDM4EMAPTNPC1
SCHEMBL31292428 0.80 DGAT1 (0.40) BRD4MAPTNPC1SMN1; SMN2RAB9A
SCHEMBL11679816 0.80 FGFR1 (0.60) FGFR1KDM4EPOLBMAPTNPC1
SCHEMBL30309791 0.80 TSHR (0.40) FGFR1BRD4KDM4EPOLBMAPT
SCHEMBL30640065 0.80 USP2 (0.40) FGFR1BRD4POLBMAPTNPC1
SCHEMBL26680112 0.80 TSHR (0.40) FGFR1BRD4KDM4EPOLBMAPT
SCHEMBL24501448 0.80 USP2 (0.40) FGFR1BRD4POLBMAPTNPC1
SCHEMBL25727797 0.80 USP2 (0.40) FGFR1BRD4POLBMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466258-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-11-27 — — EP disclosed
US-20240383875-A1 Benzimidazole Pyridine Derivatives HOFFMANN-LA ROCHE INC. (US) 2024-11-21 — — US disclosed
CN-118591534-A Novel benzimidazole pyridine derivatives 豪夫迈·罗氏有限公司 2024-09-03 — — CN disclosed
CN-116867758-A IRAK degradation agents and uses thereof 凯麦拉医疗公司 2023-10-10 — — CN disclosed
WO-2023139085-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2023-07-27 — — WO disclosed
EP-3197451-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE Merck Sharp & Dohme Corp. (US) 2017-08-02 — — EP disclosed
WO-2016049100-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383875-A1 Benzimidazole Pyridine Derivatives H1-3, H1-2, H1-4 FGFR1 902/4885BRD4 17/4885KDM4E 2122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback